Aberdeen Group’s Abiomed Inc ABMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-30,611
Closed -$7.52M 936
2022
Q3
$7.52M Buy
30,611
+11,795
+63% +$3.19M 0.02% 485
2022
Q2
$4.75M Buy
18,816
+4,073
+28% +$1.1M 0.01% 556
2022
Q1
$5.02M Sell
14,743
-752
-5% -$231K 0.01% 575
2021
Q4
$5.57M Sell
15,495
-610
-4% -$206K 0.01% 619
2021
Q3
$5.3M Buy
16,105
+1,212
+8% +$411K 0.01% 644
2021
Q2
$4.65M Sell
14,893
-631
-4% -$194K 0.01% 664
2021
Q1
$4.95M Buy
15,524
+446
+3% +$143K 0.01% 648
2020
Q4
$4.89M Buy
15,078
+1,179
+8% +$326K 0.01% 610
2020
Q3
$3.85M Sell
13,899
-2,037
-13% -$587K 0.01% 608
2020
Q2
$3.85M Sell
15,936
-1,307
-8% -$262K 0.01% 601
2020
Q1
$2.5M Sell
17,243
-270
-2% -$44.8K 0.01% 636
2019
Q4
$2.99M Sell
17,513
-179,976
-91% -$33.4M 0.01% 672
2019
Q3
$35.1M Buy
197,489
+1,227
+0.6% +$265K 0.09% 197
2019
Q2
$51.1M Buy
196,262
+35,973
+22% +$9.54M 0.11% 159
2019
Q1
$45.8M Buy
160,289
+11,278
+8% +$3.75M 0.1% 183
2018
Q4
$47.1M Buy
149,011
+24,819
+20% +$8.62M 0.11% 155
2018
Q3
$55.9M Buy
124,192
+2,095
+2% +$826K 0.1% 184
2018
Q2
$50M Sell
122,097
-9,112
-7% -$3.3M 0.1% 199
2018
Q1
$38.2M Buy
131,209
+23,930
+22% +$6.06M 0.08% 249
2017
Q4
$20.1M Buy
+107,279
New +$20M 0.04% 352

Other funds holding ABMD

Aberdeen Group's ABMD Position: Q4 2022 in Review

Aberdeen Group sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 30,611 shares — an estimated $7.52M sold.

Aberdeen Group first reported a position in ABMD in Q4 2017 and held it in 20 quarters. The position peaked at $55.9M in Q3 2018. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Aberdeen Group reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Aberdeen Group sold 30,611 Abiomed Inc shares in Q4 2022, an estimated $7.52M.
  • Aberdeen Group first reported a position in Abiomed Inc in Q4 2017 and held it in 20 quarters.
  • Aberdeen Group's Abiomed Inc position peaked at $55.9M in Q3 2018.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Aberdeen Group's 13F filing for Q4 2022, filed 10 Feb 2023.